MetaMax received Eurasian patent on a drug for the treatment of colorectal cancer

Russian biotechnology company "MetaMax" that develops innovative products for the treatment of cancer, received the Eurasian patent №017179 "Pharmaceutical composition for the treatment of hyperproliferative diseases and its application", confirming its exclusive rights to the drug MM-D37K in the member countries of the Eurasian Patent Convention and the Republic of Moldova.

Skolkovo Biomedical Cluster Resident "MetaMax" is a Russian private biotech company founded in 2010 with the goal to develop and promote innovative biopharmaceuticals for the treatment of the most common and dangerous systemic human diseases. The company was funded by Maxwell Biotech Venture Fund, created with the participation of RVC  capital, and is currently engaged in the development of its first product, MM-D37K, Russian innovative drug for the treatment of gastrointestinal  cancers, particularly colorectal, one of the most common types of cancer.

In Russia MM-D37K which has recently been approved by experts of the Eurasian Patent Office, is already protected by the Russian patent №2435783 "Chimeric peptide and pharmaceutical composition for the treatment of cancer", which was listed in Top-100 inventions of Russia in 2011, issued by the Federal intellectual property agency "Rospatent."

MM-D37K is a special case of a technological platform based on chimeric peptide sequences. As part of this platform development "MetaMax" is  conducting further R & D to find new peptide sequences using the methods of molecular modeling and preclinical PoC. This new intellectual property is also planned to be actively protected in order to expand the product portfolio for the treatment of pancreatic cancer, bladder cancer, kidney cancer and glioblastoma.

Andrey Boldyrev, CEO of "MetaMax": "Intellectual property is the most valuable asset of any innovative company, so we are really glad that the patent was obtained on the full amount of the claimed rights. "MetaMax" is planning to begin clinical trials of its leader product in early 2013, so the results of these tests will hopefully form the basis of new patent applications, and will further strengthen the legal protection of the leader product".


Anna Zelenkova,
PR director with Maxwell Biotech Group;
Tel.: +7 (495) 411-6992